UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Stocks in this Quantisnow insightHealth Care
Historical context for URGN
Across the 24 sessions after earlier URGN headlines, the stock closed higher 12 times and lower 12 times, with a median move of 3.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | URGN | SPY |
|---|---|---|---|
| Jun 2, 2026 | UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solutionand 1 other headline that session | -1.8% | +0.1% |
| May 15, 2026 | UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC | -3.0% | -1.2% |
| May 13, 2026 | ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial | +3.8% | +0.6% |
| May 11, 2026 | Ladenburg Thalmann resumed coverage on UroGen Pharma with a new price target | +6.6% | +0.2% |
| May 7, 2026 | UroGen Pharma to Present at Upcoming Investor Conferences | +1.3% | -0.3% |
| May 6, 2026 | UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights | +10.2% | +1.4% |
Quantisnow market dataNASDAQ
URGN
UroGen Pharma Ltd.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2017
Get push alerts for URGN
Full URGN profile on Quantisnow Follow URGN and get a push notification the moment its next story breaks.